Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant?

Journal of Clinical Psychiatry

Volumn 75, Issue 9, 2014, Pages e939-e944

  Gerra, Maria Lidia ^a   Marchesi, Carlo ^a   Amat, Jose A ^b   Blier, Pierre ^c   Hellerstein, David J ^b   Stewart, Jonathan W ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; ANTIDEPRESSANT AGENT; CITALOPRAM; DELAYED RELEASE FORMULATION; SEROTONIN UPTAKE INHIBITOR;

ADULT; AFFECT; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION ASSESSMENT; DOUBLE BLIND PROCEDURE; DSM-IV-TR; FEAR; FEMALE; GUILT; HAMILTON DEPRESSION RATING SCALE; HOSTILITY; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEGATIVE AFFECTIVITY; PERSONALITY; PRIORITY JOURNAL; QUICK INVENTORY OF DEPRESSIVE SYMPTOMS; RETROSPECTIVE STUDY; SOCIAL ADAPTATION; TREATMENT RESPONSE; DELAYED RELEASE FORMULATION; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATION; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AFFECT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CITALOPRAM; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84922013990     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09025     Document Type: Article

References (41)

1. Kendall PC, Watson D. Anxiety and Depression: Distinctive and Overlapping Features. New York, NY: Academic Press; 1989.
2. Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-I major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry suppl. 1996;168(suppl):17-30. PubMed
3. Fava M, Rankin MA, Wright EC, et al. Anxiety disorders in major depression. Compr Psychiatry. 2000;41(2):97-102. doi:10.1016/S010-40X(0)90140-8 PubMed
4. Melartin TK, Rytsala HJ, Leskela US, et al. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. J Clin Psychiatry. 2002;63(2):126-134. doi:10.408/JCP.v63n0207 PubMed
5. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR∗D report. Am J Psychiatry. 2008;165(3):342-351. doi:10.176/api.ajp.207.061868 PubMed
6. Fava M, Alpert JE, Carmin CN, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR∗D. Psychol Med. 2004;34(7):1299-1308. doi:10.1017/S0329170402612 PubMed
7. Fava M, Rush AJ, Alpert JE, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry. 2006;51(13):823-835. PubMed
8. Mineka S, Watson D, Clark LA. Comorbidity of anxiety and unipolar mood disorders. Annu Rev Psychol. 1998;49(1):377-412. doi:10.146/anurev.psych.49.1.37 PubMed
9. Silverstone PH, von Studnitz E. Defining anxious depression: going beyond comorbidity. Can J Psychiatry. 2003;48(10):675-680. PubMed
10. Malhi GS, Parker GB, Gladstone G, et al. Recognizing the anxious face of depression. J Nerv Ment Dis. 2002;190(6):366-373. doi:10.1097/05053-202060-04 PubMed
11. Lydiard RB. Coexisting depression and anxiety: special diagnostic and treatment issues. J Clin Psychiatry. 1991;52(suppl):48-54. PubMed
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
13. World Health Organization. The ICD-10 Classification of Mental Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992.
14. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol. 1991;100(3):316-336. doi:10.1037/021-843X.10.3.316 PubMed
15. Watson D. Intraindividual and interindividual analyses of positive and negative affect: their relation to health complaints, perceived stress, and daily activities. J Pers Soc Psychol. 1988;54(6):1020-1030. doi:10.1037/02-3514.54.6.1020 PubMed
16. Nutt DJ, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007;21(5):461-471. PubMed
17. Stahl SM. Stahl's Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008.
18. Stewart JW, McGrath PJ, Blondeau C, et al. Combination antidepressant therapy for major depressive disorder: speed and probability of remission. J Psychiatr Res. 2014;52:7-14. doi:10.1016/j.jpsychires.2013.12.01 PubMed
19. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSMIV Axis I Disorder - Patient Edition (SCID-I/P, Version 2.0). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1996.
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382 PubMed
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
22. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare; 1976:534-537.
23. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73-82. doi:10.1017/S032917030107 PubMed
24. Weissman MM, Bothwell S. Assessment of social adjustment by patient selfreport. Arch Gen Psychiatry. 1976;33(9):1111-1115. doi:10.101/archpsyc.1976.017090101010 PubMed
25. Filteau MJ, Baruch P, Lapierre YD, et al. SSRIs in anxious-agitated depression: a post-hoc analysis of 279 patients. Int Clin Psychopharmacol. 1995;10(1):51-54. doi:10.1097/04850-195030-07 PubMed
26. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997;58(4):137-145. doi:10.408/JCP.v58n0401 PubMed
27. Knutson B, Wolkowitz OM, Cole SW, et al. Selective alteration of personality and social behavior by serotonergic innervation. Am J Psychiatry. 1998;155(3):137-145 PubMed
28. Tomarken AJ, Dichter GS, Freid CM, et al. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord. 2004;78(3):235-241. doi:10.1016/S0165-0327(02)0306-3 PubMed
29. Dichter GS, Tomarken AJ, Freid CM, et al. Do venlafaxine XR and paroxetine equally influence negative and positive affect? J Affect Disord. 2005;85(3):333-339. doi:10.1016/j.jad.204.10.07 PubMed
30. Montag C, Fiebach CJ, Kirsch P, et al. Interaction of 5-HTTLPR and a variation on the oxytocin receptor gene influences negative emotionality. Biol Psychiatry. 2011;69(6):601-603. doi:10.1016/j.biopsych.2010.10.026 PubMed
31. Homberg JR, Lesch KP. Looking on the bright side of serotonin transporter gene variation. Biol Psychiatry. 2011;69(6):513-519. doi:10.1016/j.biopsych.2010.09.024 PubMed
32. Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology. 2001;25(1):131-138. doi:10.1016/S0893-13X(0)0249-9 PubMed
33. Rush AJ, Batey SR, Donahue RMJ, et al. Does pretreatment anxiety predict response to either bupropion SR or sertraline? J Affect Disord. 2001;64(1):81-87. doi:10.1016/S0165-0327(0)0250-0 PubMed
34. Papakostas GI, Stahl SM, Krishen A, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008;69(8):1287-1292. doi:10.408/JCP.v69n0812 PubMed
35. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54(6):1063-1070. doi:10.1037/02-3514.54.6.1063 PubMed
36. Shelton RC, Tomarken AJ. Can recovery from depression be achieved? Psychiatr Serv. 2001;52(11):1469-1478. doi:10.176/api.ps.52.1.1469 PubMed
37. Ghanbari R, El Mansari M, Blier P. Electrophysiological effects of the coadministration of escitalopram and bupropion on rat serotonin and norepinephrine neurons. J Psychopharmacol. 2010;24(1):39-50. doi:10.17/02698108095714 PubMed
38. Beique J, de Montigny C, Blier P, et al. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine, 1: in vivo electrophysiological studies in the rat. Neuropharmacology. 2000;39(10):1800-1812. doi:10.1016/S028-3908(0)017-4 PubMed
39. Sheehan DV, Davidson J, Manschreck T, et al. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol. 1983;3(1):28-31. PubMed
40. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 2008;33(1):88-109. doi:10.1038/sj.np.1301574 PubMed
41. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron. 2002;34(1):13-25. doi:10.1016/S0896-6273(02)0653-0 PubMed